Announcement on Preliminary Earnings Estimate for 2025
Filed with SSE · · 3 pages · Chinese
Hunan Warrant Pharmaceutical Co., Ltd. on 6ix
Earlier from Hunan Warrant Pharmaceutical
- Announcement on Voluntary Disclosure of Selection of Products for Continuation Procurement Under National Procurement Scheme After Agreement Expiry
- Announcement on Voluntary Disclosure of Receipt by the Joint-stock Company of the Phase I Clinical Study Report for ZG-002 Tablets
- Announcement on Completing Industrial and Commercial Change Registration and Obtaining Renewed Business License
- Announcement on Voluntary Disclosure of Withdrawal of Drug Registration Application
- Announcement on Resolutions of the 7th Extraordinary Meeting of the 4th Board of Directors
Later from Hunan Warrant Pharmaceutical
- Announcement on Voluntary Disclosure of Subsidiary Passing ANVISA GMP Certification
- Announcement on Voluntary Disclosure of Subsidiary Passing On-site Inspection by FDA
- Indicative Announcement on a Controlling Shareholder Adding a Person Acting in Concert and the Internal Transfer of Shares by Agreement Among Persons Acting in Concert, Resulting in Change of Equity
- Announcement on a Controlling Shareholder Adding a Person Acting in Concert and the Completion of Internal Transfer of Shares by Agreement Among Persons Acting in Concert
- Announcement on Adjusting Grant Price and Amount in 2024 Restricted Stock Incentive Plan
Follow Hunan Warrant Pharmaceutical into a list and get an email when it puts out news.
Follow Hunan Warrant Pharmaceutical